Department of Pathology, Immunology & Laboratory Medicine, University of Florida, Gainesville, FL, 32610, USA.
Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, 32610, USA.
J Neuroinflammation. 2024 Aug 17;21(1):202. doi: 10.1186/s12974-024-03196-3.
Growing evidence has implicated systemic infection as a significant risk factor for the development and advancement of Alzheimer's disease (AD). With the emergence of SARS-CoV-2 (COVID-19) and the resultant pandemic, many individuals from the same aging population vulnerable to AD suffered a severe systemic infection with potentially unidentified long-term consequences for survivors. To study the impact of COVID-19 survival on the brain's intrinsic immune system in a population also suffering from AD, we profiled post-mortem brain tissue from patients in the UF Neuromedicine Human Brain and Tissue Bank with a diagnosis of AD who survived a COVID-19 infection (COVID-AD) and contrasted our findings with AD patients who did not experience a COVID-19 infection, including a group of brain donors who passed away before arrival of SARS-CoV-2 in the United States. We assessed disease-relevant protein pathology and microglial and astrocytic markers by quantitative immunohistochemistry and supplemented these data with whole tissue gene expression analysis performed on the NanoString nCounter platform. COVID-AD patients showed slightly elevated Aβ burden in the entorhinal, fusiform, and inferior temporal cortices compared to non-COVID-AD patients, while tau pathology burden did not differ between groups. Analysis of microglia revealed a significant loss of microglial homeostasis as well as exacerbated microgliosis in COVID-AD patients compared to non-COVID-AD patients in a brain region-dependent manner. Furthermore, COVID-AD patients showed reduced cortical astrocyte numbers, independent of functional subtype. Transcriptomic analysis supported these histological findings and, in addition, identified a dysregulation of oligodendrocyte and myelination pathways in the hippocampus of COVID-AD patients. In summary, our data demonstrate a profound impact of COVID-19 infection on neuroimmune and glial pathways in AD patients persisting for months post-infection, highlighting the importance of peripheral to central neuroimmune crosstalk in neurodegenerative diseases.
越来越多的证据表明,全身感染是阿尔茨海默病(AD)发生和进展的一个重要危险因素。随着 SARS-CoV-2(COVID-19)的出现和由此产生的大流行,许多来自同一易患 AD 的老年人群体的人遭受了严重的全身感染,对幸存者可能存在潜在的长期影响。为了研究 COVID-19 幸存者对患有 AD 的人群大脑固有免疫系统的影响,我们对 UF 神经医学人类大脑和组织库中患有 AD 并幸存 COVID-19 感染(COVID-AD)的患者死后脑组织进行了分析,并将我们的发现与未经历 COVID-19 感染的 AD 患者进行了对比,包括一组在 SARS-CoV-2 抵达美国之前去世的脑捐献者。我们通过定量免疫组织化学评估了与疾病相关的蛋白质病理学以及小胶质细胞和星形胶质细胞标志物,并通过 NanoString nCounter 平台上进行的全组织基因表达分析补充了这些数据。与非 COVID-AD 患者相比,COVID-AD 患者的内嗅皮质、梭状回和下颞叶皮质中的 Aβ 负担略有升高,而两组之间的 tau 病理学负担没有差异。小胶质细胞分析显示,与非 COVID-AD 患者相比,COVID-AD 患者的小胶质细胞稳态明显丧失,并且小胶质细胞增生加剧,这在脑区依赖性方式中有所不同。此外,COVID-AD 患者表现出皮质星形胶质细胞数量减少,而与功能亚型无关。转录组分析支持这些组织学发现,此外,还确定了 COVID-AD 患者海马体中少突胶质细胞和髓鞘形成途径的失调。总之,我们的数据表明 COVID-19 感染对 AD 患者的神经免疫和神经胶质途径产生了深远的影响,这种影响在感染后持续数月,强调了外周到中枢神经免疫串扰在神经退行性疾病中的重要性。